Effectiveness of novel iron regulators in the treatment of diabetic nephropathy

• Authors: Dekai Banerjee , Ginpreet Kaur , Bappaditya Chatterjee , Hemant Joshi , Seema Ramniwas , Hardeep Singh Tuli

Abstracts

EN

Introduction and aim. The novel advancements of upcoming iron regulators used to treat diabetic nephropathy have implicated a common manifestation of combination chelation therapy used to eliminate end-stage renal disease associated with inflammation and iron imbalance that is altered by renal iron absorption. However, iron accumulation in the clustered kidneys that filter blood may cause problems that affect diabetic blood sugar regulation. Material and methods. A well-designed method was employed to discover relevant research publications on iron chelators and their potential to treat diabetic nephropathy. “Iron chelators”, “diabetic nephropathy”, “end-stage renal disease”, and “chelation therapy” were searched in Google Scholar, Web of Science, PubMed, and EMBASE. Analysis of literature. Although the specific etiology and development have not been fully explored, emerging evidence on iron pathophysiology helps comprehend the pathogenesis of acute kidney damage and chronic kidney disease, which crucially provides novel iron chelation therapy techniques. Ferroptosis and hepcidin marker proteins increase oxidative/nitrifying stress and kidney injury. Iron chelator medicines including deferoxamine, deferasirox, and deferiprone were tested as prophylactic strategies. Conclusion. This article covers both preclinical and clinical aspects of iron chelators to avoid diabetic nephropathy, including novel iron therapies that must be reviewed when selecting dosing regimens.

Keywords

EN

acute kidney injury; chronic kidney disease; end-stage renal disease; iron chelators; renal iron handling

• Publisher: Uniwersytet Rzeszowski. Wydawnictwo Uniwersytetu Rzeszowskiego
• Journal: European Journal of Clinical and Experimental Medicine
• Year: 2023
• Issue: 3
• Pages: 639-647

Dates

published

2023

Contributors

author

Dekai Banerjee

• SVKM’s Narsee Monjee Institute of Management Studies, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Mumbai, India

author

Ginpreet Kaur

• SVKM’s Narsee Monjee Institute of Management Studies, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Mumbai, India

author

Bappaditya Chatterjee

• SVKM’s Narsee Monjee Institute of Management Studies, Shobhaben Pratapbhai Patel School of Pharmacy and Technology Management, Mumbai, India

author

Hemant Joshi

• School of Biotechnology, Jawaharlal Nehru University, New Delhi, India

author

Seema Ramniwas

• University Centre for Research and Development, University Institute of Pharmaceutical Sciences, Chandigarh University, Gharuan, Mohali, India

author

Hardeep Singh Tuli

• Department of Bio-Sciences and Technology, Maharishi Markandeshwar Engineering Coollege, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala, India

Identifiers

DOI

10.15584/ejcem.2023.3.28

Biblioteka Nauki

29519511